End-to-end partner to accelerate your oncology antibody program

Complex and traditionally “undruggable” targets require tailored discovery strategies rather than a one-size-fits-all campaign. For intracellular tumor antigens, we access them through neoantigen-derived peptide–MHC antibody discovery, combining a dedicated MHC–peptide complex antibody service, TCR-like phage display, and custom neopeptide synthesis, with a minimum of three unique binders guaranteed. For immune checkpoints, we generate functional antibodies against targets presented in their native membrane conformation, supported by AI-powered epitope mapping to precisely characterize binding. The same approach extends to self-antigens and other challenging membrane proteins.

It is the world’s first human cancer patient-derived phage display library, built from the immune repertoires of 86 cancer patients across 18 indications. With 6.8 × 10¹⁰ clones available in both scFv and Fab formats, it offers high diversity and clinically relevant repertoires to target difficult oncology antigens. Because the antibodies are fully human from the outset, no humanization step is required, which reduces both timelines and immunogenicity risk. The library is suitable for neoantigens, self-antigens, MHC–peptide complexes, and immune checkpoints, and typically delivers tumor-specific candidates in around four weeks.

AI is used as an accelerator within the antibody development workflow, not as a replacement for experimental validation. Our AIxplore platform helps generate and prioritize candidate sequences faster, after which every candidate’s potential is confirmed through in-house wet-lab validation. This synergy between in silico design and in vitro confirmation also powers downstream services such as AI-guided affinity maturation (up to a 1,000-fold improvement in roughly six weeks), AI-assisted humanization, and AI-powered epitope/paratope mapping. The result is a faster, more predictable path while keeping experimental evidence at the core of every decision.

The right format depends on your antigen type, desired modality, project timeline, developability constraints, and intended downstream application. We help you select and engineer the appropriate format, with proven track records across CAR-T binders (e.g., 130 validated candidates in three weeks for a breast cancer program), VHH candidates (e.g., PD-1-targeting VHHs for NSCLC research), bispecific antibodies (e.g., seven formats yielding nanomolar leads against prostate cancer), and ADCs (e.g., ovarian cancer proof-of-concept studies). Rather than committing to a format upfront, you can define your target with our scientists and let the data guide the most suitable engineering route.

For patient-derived discovery campaigns, fully human tumor-specific antibodies are typically delivered in around four weeks, with a minimum of three validated therapeutic binders per project. For complex targets addressed with our AID-Cancer libraries, success rates reach up to 95%. You retain full ownership of all generated antibody sequences, with no royalties, and because the antibodies are fully human, no humanization is required. From there, candidates can move directly into engineering and bioproduction within the same end-to-end workflow.